A researcher from Chesterfield, Missouri, Thomas (Tom) Brutnell, PhD, has spent 25 years as a principal investigator studying genomes, genetics, and molecular biology. Dr Thomas Brutnell, the founder of Viridis Genomics Consulting, LLC, has interests in Chinese medicinal plants, plant tissue culture and transformation, and synthetic biology.
A January 2023 article in the business publication, BigThink, reported that the market for synthetic biology is poised for growth. The current global synthetic biology market was valued at $10.11 billion in 2021, with a possible growth of $32.73 billion in 2028. Further, this is based on a compounded annual growth rate of 27.1 percent between 2022 and 2028.
Synthetic biology involves redesigning or reconstructing biological entities to advance processes. The technology has been around since the early 1980s when it revolutionized insulin production by inserting a human gene into a bacterium. In essence, the technology engineers microbes as a part of biomanufacturing using enzymes, chemicals, and other bio-based materials.
Two companies are leading the way in using synthetic biology. Bayer partner, Gingko BioWorks, uses the technology to help other innovators manufacture plastic munching microbes and improve beauty products. Inscripta uses its CRISPR genome editing technology to produce chemical and bio-based products. This company’s genome technology has gone beyond simply reading DNA to writing it to accelerate biomanufacturing.